Table 1.

Baseline characteristics of patients in the erenumab clinical trials [31, 43]

Characteristic	Episodic migrainea (NCT02456740)		Chronic migraineb (NCT02066415)
Group	Placebo	Erenumab 140 mg	Placebo	Erenumab 140 mg
Number of patients	319	319	286	190
Mean age (SD)	41.3 (11.2)	40.4 (11.1)	42.1 (11.3)	42.9 (11.1)
Sex, n (%)
Male	45 (14.1)	47 (14.7)	60 (21.0)	30 (15.8)
Female	274 (85.9)	272 (85.3)	226 (79.0)	160 (84.2)
Race, n (%)
White	277 (86.8)	293 (91.8)	268 (93.7)	184 (96.8)
Black	24 (7.5)	18 (5.6)	11 (3.8)	6 (3.2)
Other	18 (5.6)	8 (2.5)	7 (2.4)	0 (0.0)
Baseline MMD	8.2 (± 2.5)	8.3 (± 2.5)	18.2 (± 4.7)	17.8 (± 4.7)

n number, MMD monthly migraine days, SD standard deviation

^aDefined as patients experiencing 4–14 headache days per 28 days, 4–14 migraine days per 28 days

^bDefined as patients experiencing ≥15 headache days per 28 days, ≥8 migraine days per 28 days